Trevi Therapeutics: Funding, Investors & Team (Oct 2026)
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Trevi Therapeutics has raised $393M across 4 funding rounds on record, the most recent an undisclosed round of $173M announced in Apr 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Trevi Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Trevi Therapeutics Funding Rounds
Trevi Therapeutics raised $55.0M in a Post-IPO Equity announced in Apr 2022.
2.7 years later, an undisclosed round of $50.0M was announced in Dec 2024.
6 months later, an undisclosed round of $115M was announced in Jun 2025.
10 months later, an undisclosed round of $173M was announced in Apr 2026.
Trevi Therapeutics Founders and Leadership Team
Contact details for the Trevi Therapeutics team: 2 of 3 have an email address on file.
Start 14-day free trial →Trevi Therapeutics Funding Compared to Other Biotechnology Startups
Trevi Therapeutics' latest round of $173M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Trevi Therapeutics in Biotechnology and Sandy Hook
Companies Similar to Trevi Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Trevi Therapeutics Funding FAQs
What does Trevi Therapeutics do?
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
How much funding has Trevi Therapeutics raised?
Trevi Therapeutics has raised $393M across 4 rounds on record. The most recent is an undisclosed round of $173M announced in Apr 2026.
When did Trevi Therapeutics last raise funding?
Trevi Therapeutics' most recent funding round on record is an undisclosed round of $173M, announced in Apr 2026.
Who founded Trevi Therapeutics?
FundedIQ lists Jennifer L Good (Founder), Thomas R Sciascia (Founder) at Trevi Therapeutics.
Who is the CEO of Trevi Therapeutics?
Jennifer Good is listed as CEO at Trevi Therapeutics.
Where is Trevi Therapeutics headquartered?
Trevi Therapeutics is based in Sandy Hook, Connecticut, United States.
How many employees does Trevi Therapeutics have?
Trevi Therapeutics is in the 11-50 employee band.
How does Trevi Therapeutics' funding compare to other Biotechnology startups?
Trevi Therapeutics' latest round of $173M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Trevi Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Trevi Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.